HURA news

Latest 1 stories · newest Nov 13, 2026

HURA

TuHURA reports 2026 Q3 results and announces FDA clearance for Phase 1b study.

Management reported Q3 2026 financial results and a $50 million credit facility. Additionally, the FDA granted clearance to initiate a Phase 1b study of TBS-2025 for r/r NPM1 AML.

Earnings Nov 13, 2026 sentiment +0.80 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same HURA feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/HURA/newsSTART FREE